Menzies-Gow AN - Search Results

1

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.

Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Flood-Page PT, et al. Am J Respir Crit Care Med. 2003 Jan 15;167(2):199-204. doi: 10.1164/rccm.200208-789OC. Epub 2002 Oct 17. Am J Respir Crit Care Med. 2003. PMID: 12406833 Clinical Trial.

2

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial.

Menzies-Gow A, Corren J, Bel EH, Maspero J, Heaney LG, Gurnell M, Wessman P, Martin UJ, Siddiqui S, Garcia Gil E. Menzies-Gow A, et al. ERJ Open Res. 2019 Sep 25;5(3):00009-2019. doi: 10.1183/23120541.00009-2019. eCollection 2019 Jul. ERJ Open Res. 2019. PMID: 31579676 Free PMC article.

3

Eosinophil chemokines and their receptors: an attractive target in asthma?

Menzies-Gow A, Robinson DS. Menzies-Gow A, et al. Lancet. 2000 May 20;355(9217):1741-3. doi: 10.1016/S0140-6736(00)02258-3. Lancet. 2000. PMID: 10832821 No abstract available.

4

Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma.

Menzies-Gow A, Robinson DS. Menzies-Gow A, et al. Curr Opin Pulm Med. 2002 Jan;8(1):33-8. doi: 10.1097/00063198-200201000-00006. Curr Opin Pulm Med. 2002. PMID: 11753121 Review.

5

Eosinophil chemokines and chemokine receptors: their role in eosinophil accumulation and activation in asthma and potential as therapeutic targets.

Menzies-Gow A, Robinson DS. Menzies-Gow A, et al. J Asthma. 2001 Dec;38(8):605-13. doi: 10.1081/jas-100107538. J Asthma. 2001. PMID: 11758889 Review. No abstract available.

6

Eotaxin (CCL11) and eotaxin-2 (CCL24) induce recruitment of eosinophils, basophils, neutrophils, and macrophages as well as features of early- and late-phase allergic reactions following cutaneous injection in human atopic and nonatopic volunteers.

Menzies-Gow A, Ying S, Sabroe I, Stubbs VL, Soler D, Williams TJ, Kay AB. Menzies-Gow A, et al. J Immunol. 2002 Sep 1;169(5):2712-8. doi: 10.4049/jimmunol.169.5.2712. J Immunol. 2002. PMID: 12193745 Free article.

7

Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics.

Menzies-Gow A, Flood-Page P, Sehmi R, Burman J, Hamid Q, Robinson DS, Kay AB, Denburg J. Menzies-Gow A, et al. J Allergy Clin Immunol. 2003 Apr;111(4):714-9. doi: 10.1067/mai.2003.1382. J Allergy Clin Immunol. 2003. PMID: 12704348 Clinical Trial.

8

Eosinophils and interleukin-5: the debate continues.

Kay AB, Menzies-Gow A. Kay AB, et al. Am J Respir Crit Care Med. 2003 Jun 15;167(12):1586-7. doi: 10.1164/rccm.2304001. Am J Respir Crit Care Med. 2003. PMID: 12796050 Review. No abstract available.

9

Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.

Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. Flood-Page P, et al. J Clin Invest. 2003 Oct;112(7):1029-36. doi: 10.1172/JCI17974. J Clin Invest. 2003. PMID: 14523040 Free PMC article. Clinical Trial.

10

Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin.

Phipps S, Flood-Page P, Menzies-Gow A, Ong YE, Kay AB. Phipps S, et al. J Invest Dermatol. 2004 Jun;122(6):1406-12. doi: 10.1111/j.0022-202X.2004.22619.x. J Invest Dermatol. 2004. PMID: 15175031 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results